Autophagy facilitates the Lapatinib resistance of HER2 positive breast cancer cells

Medical Hypotheses

Volumn 77, Issue 2, 2011, Pages 206-208

  Chen, Suning ^a   Li, Xiumin ^b   Feng, Juan ^a   Chang, Ying ^a   Wang, Zhirui ^a   Wen, Aidong ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLADENINE; AUTOPHAGY PROTEIN 5; BAFILOMYCIN A1; CHLOROQUINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HYDROXYCHLOROQUINE; LAPATINIB; SHORT HAIRPIN RNA;

ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; BREAST CANCER; CANCER RESISTANCE; CELL SURVIVAL; EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; IN VITRO STUDY; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; AUTOPHAGY; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MODELS, BIOLOGICAL; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, ERBB-2;

EID: 79960644581     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.04.013     Document Type: Article

References (37)

1. Curigliano G., Viale G., Bagnardi V., Fumagalli L., Locatelli M., Rotmensz N., et al. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 2009, 27:5693-5699.
2. Pommier S.J., Quan G.G., Christante D., Muller P., Newell A.E., Olson S.B., et al. Characterizing the HER2/neu status and metastatic potential of breast cancer stem/progenitor cells. Ann Surg Oncol 2010, 17:613-623.
3. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
4. Geyer C.E., Forster J., Lindquist D., Chan S., Romieu C.G., Pienkowski T., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355:2733-2743.
5. Macfarlane R.J., Gelmon K.A. Lapatinib for breast cancer: a review of the current literature. Expert Opin Drug Saf 2011, 10:109-121.
6. Esteva F.J., Yu D., Hung M.C., Hortobagyi G.N. Molecular predictors of response to trastuzumab and Lapatinib in breast cancer. Nat Rev Clin Oncol 2010, 7:98-107.
7. Gomez H.L., Doval D.C., Chavez M.A., Ang P.C., Aziz Z., Nag S., et al. Efficacy and safety of Lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008, 26:2999-3005.
8. Liu L., Greger J., Shi H., Liu Y., Greshock J., Annan R., et al. Novel mechanism of Lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res 2009, 69:6871-6878.
9. Xia W., Bacus S., Husain I., Liu L., Zhao S., Liu Z., et al. Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA. Mol Cancer Ther 2010, 9:292-299.
10. Hynes N.E., Dey J.H. PI3K inhibition overcomes trastuzumab resistance. blockade of ErbB2/ErbB3 is not always enough. Cancer Cell 2009, 15:353-355.
11. Berns K., Horlings H.M., Hennessy B.T., Madiredjo M., Hijmans E.M., Beelen K., et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402.
12. Park B.H., Davidson N.E. PI3 kinase activation and response to trastuzumab therapy: what's neu with herceptin resistance?. Cancer Cell 2007, 12:297-299.
13. Zoppoli G., Moran E., Soncini D., Cea M., Garuti A., Rocco I., et al. ras-Induced resistance to lapatinib is overcome by MEK inhibition. Curr Cancer Drug Targets 2010, 10:168-175.
14. Martin A.P., Mitchell C., Rahmani M., Nephew K.P., Grant S., Dent P. Inhibition of MCL-1 enhances Lapatinib toxicity and overcomes Lapatinib resistance via BAK-dependent autophagy. Cancer Biol Ther 2009, 8:2084-2096.
15. Martin A.P., Miller A., Emad L., Rahmani M., Walker T., Mitchell C., et al. Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation. Mol Pharmacol 2008, 74:807-822.
16. Levine B., Klionsky D.J. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 2004, 6:463-477.
17. Mathew R., Karantza-Wadsworth V., White E. Role of autophagy in cancer. Nat Rev Cancer 2007, 7:961-967.
18. Xie Z., Klionsky D.J. Autophagosome formation: core machinery and adaptations. Nat Cell Biol 2007, 9:1102-1109.
19. Tanida I. Autophagosome formation and molecular mechanism of autophagy. Antioxid Redox Signal 2010, [Epub ahead of print].
20. Hara T., Nakamura K., Matsui M., Yamamoto A., Nakahara Y., Suzuki-Migishima R., et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006, 441:885-889.
21. Komatsu M., Waguri S., Chiba T., Murata S., Iwata J., Tanida I., et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006, 441:880-884.
22. Aguirre-Ghiso J.A. The problem of cancer dormancy: understanding the basic mechanisms and identifying therapeutic opportunities. Cell Cycle 2006, 5:1740-1743.
23. Degenhardt K., Mathew R., Beaudoin B., Bray K., Anderson D., Chen G., et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 2006, 10:51-64.
24. Jin S., White E. Role of autophagy in cancer: management of metabolic stress. Autophagy 2007, 3:28-31.
25. Karantza-Wadsworth V., Patel S., Kravchuk O., Chen G., Mathew R., Jin S., et al. Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. Genes Dev 2007, 21:1621-1635.
26. Liang X.H., Jackson S., Seaman M., Brown K., Kempkes B., Hibshoosh H., et al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 1999, 402:672-676.
27. Qu X., Yu J., Bhagat G., Furuya N., Hibshoosh H., Troxel A., et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest 2003, 112:1809-1820.
28. Marino G., Salvador-Montoliu N., Fueyo A., Knecht E., Mizushima N., Lopez-Otin C. Tissue-specific autophagy alterations and increased tumorigenesis in mice deficient in Atg4C/autophagin-3. J Biol Chem 2007, 282:18573-18583.
29. Karantza-Wadsworth V., White E. Role of autophagy in breast cancer. Autophagy 2007, 3:610-613.
30. Chen S., Rehman S.K., Zhang W., Wen A., Yao L., Zhang J. Autophagy is a therapeutic target in anticancer drug resistance. Biochim Biophys Acta 2010, 1806:220-229.
31. Vazquez-Martin A., Oliveras-Ferraros C., Menendez J.A. Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab. PLoS One 2009, 4:e6251.
32. Bellodi C., Lidonnici M.R., Hamilton A., Helgason G.V., Soliera A.R., Ronchetti M., et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 2009, 119:1109-1123.
33. Kawai A., Uchiyama H., Takano S., Nakamura N., Ohkuma S. Autophagosome-lysosome fusion depends on the pH in acidic compartments in CHO cells. Autophagy 2007, 3:154-157.
34. Kim P.K., Hailey D.W., Mullen R.T., Lippincott-Schwartz J. Ubiquitin signals autophagic degradation of cytosolic proteins and peroxisomes. Proc Natl Acad Sci USA 2008, 105:20567-20574.
35. Rzymski T., Milani M., Singleton D.C., Harris A.L. Role of ATF4 in regulation of autophagy and resistance to drugs and hypoxia. Cell Cycle 2009, 8:3838-3847.
36. Milani M., Rzymski T., Mellor H.R., Pike L., Bottini A., Generali D., et al. The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib. Cancer Res 2009, 69:4415-4423.
37. Martinet W., De Meyer G.R., Andries L., Herman A.G., Kockx M.M. In situ detection of starvation-induced autophagy. J Histochem Cytochem 2006, 54:85-96.